Use of non-steroidal anti-inflammatory drugs and survival following breast cancer diagnosis
Menée aux Etats-Unis auprès de 1 024 participantes, cette étude analyse l'impact de la prise de médicaments anti-inflammatoires non stéroïdiens avant le diagnostic sur la survie de patientes atteintes d'un cancer du sein
Background: While there is accumulating evidence that use of non-steroidal anti-inflammatory drugs (NSAIDs) decreases breast cancer risk, little is known about the impact of NSAIDs on survival after breast cancer diagnosis. Methods: We assessed whether recent, pre-diagnostic NSAID use and lifetime cumulative aspirin use before diagnosis were associated with survival among 1,024 women with incident, primary, invasive breast cancer. Results: Recent, pre-diagnostic use of aspirin, ibuprofen, and acetaminophen, and lifetime use of aspirin up to diagnosis were not associated with either all-cause mortality or breast cancer specific mortality. Neither dose nor frequency of use was associated with risk. Associations were not different for pre- and post-menopausal women. Conclusions: In our data, pre-diagnostic NSAID use and lifetime cumulative aspirin use were not associated with breast cancer survival. Impact: Our findings do not support a role of NSAIDs prior to diagnosis in breast cancer survival.